Treatment patterns, health-related quality of life and adherence to prophylaxis among haemophilia A patients in the United States

Haemophilia

Volumn 18, Issue 5, 2012, Pages 760-765

  Duncan, N ^a   Shapiro, A ^a   Ye, X ^b   Epstein, J ^c   Luo, M P ^b  

^a INDIANA HEMOPHILIA AND THROMBOSIS CENTER   (United States)

^b Baxter Bioscience   (United States)

^c BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

Adherence; Adolescent; Health related quality of life; On demand; Paediatric; Prophylaxis

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CAREGIVER; CHILD; CLINICAL EVALUATION; DISEASE SEVERITY; FAMILY; FEMALE; HEALTH SURVEY; HEMOPHILIA A; HUMAN; MAJOR CLINICAL STUDY; MALE; PEDIATRICS; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; SCHOOL CHILD; SHORT FORM 12; TREATMENT PLANNING; UNITED STATES;

ADOLESCENT; ADULT; AGE FACTORS; CHILD; CROSS-SECTIONAL STUDIES; DATA COLLECTION; ELECTRONIC MAIL; FACTOR VIII; HEMARTHROSIS; HEMOPHILIA A; HUMANS; MALE; PATIENT COMPLIANCE; QUALITY OF LIFE; SELF ADMINISTRATION; UNITED STATES;

EID: 84865558828     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2012.02813.x     Document Type: Article

References (25)

1. Klamroth R, Pollmann H, Hermans C et al. The relative burden of haemophilia A and the impact of target joint development on health-related quality of life: results from the ADVATE Post-Authorization Safety Surveillance (PASS) study. Haemophilia 2011; 17: 412-21.
2. Fischer K, van der Bom JG, van den Berg HM. Health-related quality of life as outcome parameter in haemophilia treatment. Haemophilia 2003; 9(Suppl. 1): 75-81 discussion 2.
3. Berntorp E, Boulyjenkov V, Brettler D et al. Modern treatment of haemophilia. Bull World Health Organ 1995; 73: 691-701.
4. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
5. Ljung RC. Aspects of haemophilia prophylaxis in Sweden. Haemophilia 2002; 8(Suppl. 2): 34-7.
6. Lofqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients - a long-term follow-up. J Intern Med 1997; 241: 395-400.
7. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
8. MASAC recommendation concerning prophylaxis (Regular administration of clotting factor concentrate to prevent bleeding). 2007. Available at: http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=1007. Accessed April 18, 2012.
9. Collins P, Faradji A, Morfini M, Enriquez MM, Schwartz L. Efficacy and safety of secondary prophylactic versus on-demand sucrose-formulated recombinant factor viii treatment in adults with severe hemophilia a: results from a 13-month crossover study. J Thromb Haemost 2010; 8: 83-9.
10. Fischer K, van der Bom JG, Molho P et al. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia 2002; 8: 745-52.
11. Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia 2001; 7: 392-6.
12. Thornburg CD, Pipe SW. Adherence to prophylactic infusions of factor VIII or factor IX for haemophilia. Haemophilia 2006; 12: 198-9.
13. Petrini P. Identifying and overcoming barriers to prophylaxis in the management of haemophilia. Haemophilia 2007; 13(Suppl. 2): 16-22.
14. Thornburg CD. Physicians' perceptions of adherence to prophylactic clotting factor infusions. Haemophilia 2008; 14: 25-9.
15. De Moerloose P, Urbancik W, Van Den Berg HM, Richards M. A survey of adherence to haemophilia therapy in six European countries: results and recommendations. Haemophilia 2008; 14: 931-8.
16. du Treil S, Rice J, Leissinger CA. Quantifying adherence to treatment and its relationship to quality of life in a well-characterized haemophilia population. Haemophilia 2007; 13: 493-501.
17. Fischer K, Van Den Berg M. Prophylaxis for severe haemophilia: clinical and economical issues. Haemophilia 2003; 9: 376-81.
18. Varni JW, Seid M, Kurtin PS. PedsQL™ 4.0: reliability and validity of the Pediatric Quality of Life Inventory™ Version 4.0 generic core scales in healthy and patient populations. Med Care 2001; 39: 800-12.
19. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34: 220-33.
20. Duncan N, Kronenberger W, Roberson C, Shapiro A. VERITAS-Pro: a new measure of adherence to prophylactic regimens in haemophilia. Haemophilia 2010; 16: 247-55.
21. Zhou ZY, Wu J, Baker J et al. Haemophilia Utilization Group Study - Part Va (HUGS Va): design, methods and baseline data. Haemophilia 2011; 17: 729-36.
22. Khair K, Lawrence K, Butler R, O'Shea E, Christie BA. Assessment of treatment practice patterns for severe hemophilia a: a global nurse perspective. Acta Haematol 2008; 119: 115-23.
23. Geraghty S, Dunkley T, Harrington C, Lindvall K, Maahs J, Sek J. Practice patterns in haemophilia A therapy - global progress towards optimal care. Haemophilia 2006; 12: 75-81.
24. Tebbi CK. Treatment compliance in childhood and adolescence. Cancer 1993; 71: 3441-9.
25. Fischer K, Collins P, Astermark J. Internal and external determinants of bleeding patterns on prophylaxis for severe haemophilia A. Blood 2007; 110: 1145.